MedTrace Logo

Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma

NCT05221398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 517

Last updated 2024-09-25

No results posted yet for this study

Summary

Though hepatectomy is the best treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. No study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.

Conditions

Interventions

DRUG

Immune Checkpoint Inhibitors Based Adjuvant therapy

Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy

OTHER

Active surveillance

Patients in this group only receive active surveillance

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-03
Primary Completion
2023-01-18
Completion
2023-03-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221398 on ClinicalTrials.gov